Stock Scorecard
Stock Summary for DermTech Inc (DMTK) - $0.62 as of 4/16/2024 1:09:18 PM EST
Total Score
16 out of 29
Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for DMTK
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for DMTK
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for DMTK
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for DMTK
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for DMTK
Financial Details for DMTK
Company Overview |
|
|---|---|
| Ticker | DMTK |
| Company Name | DermTech Inc |
| Country | USA |
| Description | DermTech, Inc., a molecular diagnostics company, develops and markets new non-invasive genomic tests to diagnose skin cancer, inflammatory diseases, and age-related conditions in the United States. The company is headquartered in La Jolla, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | SERVICES-MEDICAL LABORATORIES |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/2/2024 |
Stock Price History |
|
| Last Day Price | 0.62 |
| Last Day Price Updated | 4/16/2024 1:09:18 PM EST |
| Last Day Volume | 101,215 |
| Average Daily Volume | 300,756 |
| 52-Week High | 4.67 |
| 52-Week Low | 0.61 |
| Last Price to 52 Week Low | 1.64% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 266.04 |
| Sector PE | 62.54 |
| 5-Year Average PE | -4.49 |
| Free Cash Flow Ratio | 0.39 |
| Industry Free Cash Flow Ratio | 16.33 |
| Sector Free Cash Flow Ratio | 32.12 |
| Current Ratio Most Recent Quarter | 4.59 |
| Total Cash Per Share | 1.61 |
| Book Value Per Share Most Recent Quarter | 1.66 |
| Price to Book Ratio | 0.38 |
| Industry Price to Book Ratio | 2.75 |
| Sector Price to Book Ratio | 22.02 |
| Price to Sales Ratio Twelve Trailing Months | 1.41 |
| Industry Price to Sales Ratio Twelve Trailing Months | 1.52 |
| Sector Price to Sales Ratio Twelve Trailing Months | 7.31 |
Share Statistics |
|
| Total Shares Outstanding | 34,623,400 |
| Market Capitalization | 21,466,508 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 13.54% |
| Reported EPS 12 Trailing Months | -3.09 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -3.14 |
| Net Income Twelve Trailing Months | -100,888,000 |
| Net Income Past Year | -100,888,000 |
| Net Income Prior Year | -116,683,000 |
| Quarterly Revenue Growth YOY | 31.10% |
| 5-Year Revenue Growth | 111.20% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 55,864,000 |
| Total Cash Past Year | 55,864,000 |
| Total Cash Prior Year | 104,740,000 |
| Net Cash Position Most Recent Quarter | 55,864,000 |
| Net Cash Position Past Year | 55,864,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 57,175,000 |
| Total Stockholder Equity Prior Year | 107,242,000 |
| Total Stockholder Equity Most Recent Quarter | 57,175,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.07 |
| MACD Signal | -0.09 |
| 20-Day Bollinger Lower Band | 0.37 |
| 20-Day Bollinger Middle Band | 1.11 |
| 20-Day Bollinger Upper Band | 1.86 |
| Beta | 2.56 |
| RSI | 33.31 |
| 50-Day SMA | 1.77 |
| 200-Day SMA | 14.67 |
System |
|
| Modified | 4/15/2024 10:38:37 PM EST |